Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOB1-TCR therapy for relapsed or refractory B-cell malignancies
2024-515900-38-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LUMC-BOB1-B7-TCR.1 in B cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Leiden University Medical Center. Planned start Aug 2025; status: authorised.
02
Drugs
LUMC-BOB1-B7-TCR.1
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)multiple myeloma (MM)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2024-515900-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515900-38-00.